AbbVie Assumes Two Interchangeable Humira Biosimilars In 2023

Up To Nine Adalimumab Biosimilars to Launch In Key Year

 
• By Dean Rudge

Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.

Billion_Dollar
Humira was a $15bn opportunity in the US in 2019 • Source: Shutterstock

More from Biosimilars

More from Products